OOIR: Observatory of International Research

Papers

(The TQCC of Xenobiotica is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
A cysteine trapping assay for risk assessment of reactive acyl CoA metabolites	19
Evaluation of urinary acetaminophen metabolites and its association with the genetic polymorphisms of the metabolising enzymes, and serum acetaminophen concentrations in preterm neonates with patent d	18
Utility of preclinical species for uncertainty assessment and correction of prediction of human volume of distribution using the Rodgers-Lukacova model	16
Developmental stage and infection status may affect drug distribution in the prostate of rats	14
Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study	12
Estimation of contribution of CYP2D6 to tipepidine metabolism in humans and prolongation of the half-life of tipepidine by combination use with a CYP2D6 inhibitor in chimeric mice with humanised liver	10
In vitro hepatic metabolism of the natural product quebecol	10
One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development	9
Academic foreign compound metabolism – ‘ quo vadis ’?	9
Meeting report: oligonucleotide ADME workshop	8
Diisononyl phthalate down-regulates the expression of antioxidant genes NFE2L2 , TXN , and TXNRD2 , while d	8
In silico models to predict tubular secretion or reabsorption clearance pathway using physicochemical properties and structural characteristics	8
Nrf2 signaling pathway studies in Drosophila melanogaster : parallel roles in human health and insect environmental responses	8
Formulation of apigenin-loaded solid lipid nanoparticles: characterisation, molecular docking, and anticancer assay	8
Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients	7
Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers	7
Comparisons between human and rodent hepatic glutathione S-Transferase activities reveal sex and species differences	7
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor	7
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 1 and 2 (rs4244285, 681G>A) alleles in vitro	7
Metabolic activation of zolmitriptan mediated by CYP2D6	7
Metabolic map of the antiviral drug podophyllotoxin provides insights into hepatotoxicity	7
Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2	7
Role of amino acids at positions 34, 296, and 486 of cytochrome P450 2D6 in the stimulatory and inhibitory effects of psychotropic agents on dopamine formation from p-tyramine	7
Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver	7
Preparation, characterisation, pharmacokinetics and distribution of esculin microspheres administered via intravitreal injection into rabbit brain	7

Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions	7
Oxidative metabolism of razuprotafib (AKB-9778), a sulfamic acid phosphatase inhibitor, in human microsomes and recombinant human CYP2C8 enzyme	7
In vivo evaluation of pharmacokinetic drug–drug interactions between fluorinated pyrimidine anticancer drugs, 5-fluorouracil and capecitabin, and an anticoagulant, warfarin	6
Exploring precision-cut liver slices for comparative xenobiotic metabolism profiling in swine and cattle	6
Safflower yellow for injection enhances anti-coagulation of warfarin in rats: implications in pharmacodynamics and pharmacokinetics	6
Machine learning-driven bioavailability prediction in early-stage drug development: a KNIME-based computational workflow for digital health applications	6
New era in bioequivalence global harmonization through ICH M13 initiative: critical review on new concepts, alternative approaches for high-risk products	6
Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats	6
N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population	6
Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation	6
The effect of ARVs on the MEKKK1 gene promoter, inflammatory cytokine expression and signalling in acute treated Jurkat T cells	6
An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds	6
Arctigenin-induced erythrocyte membrane remodelling is mediated through calcium influx, metabolic collapse, and casein kinase 1α	6
Beyond cytotoxic potency: disposition features required to design ADC payload	6
2-Oxidation, 3-methyl hydroxylation, and 6-hydroxylation of skatole, a contributor to the odour of boar-tainted pork meat, mediated by porcine liver microsomal cytochromes P450 1A2, 2A19, 2E1, and 3A2	6
Effects of the total flavonoid extracts and the monomers of Daphne genkwa on CYP2C8 activity	6
Adenine-related compounds modulate UDP-glucuronosyltransferase (UGT) activity in mouse liver microsomes	6
Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P ₁ modulator ponesimod	6
Preclinical pharmacokinetic investigation of the bioavailability and skin distribution of HY-072808 ointment, a novel drug candidate for the treatment of atopic dermatitis, in minipigs by a newly LC-M	6
Absorption, distribution, metabolism, and excretion of [¹⁴C]TPN729 after oral administration to rats	6
Experimental and computational models to investigate intestinal drug permeability and metabolism	6
Development of eugenol-fortified fisetin-loaded nano-invasomes gel	6
Bioavailability, safety and tolerability of intravenous brivaracetam in healthy Japanese participants	5
Nano-pharmacokinetics and pharmacodynamics of green-synthesized ZnO nanoparticles: a pathway to safer therapeutic applications	5
Elucidation of clearance mechanism of TP0463518, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor: does a species difference in excretion routes exist between humans and animals?	5
Pharmacokinetics and metabolic disposition of a potent and selective kynurenine monooxygenase inhibitor, CHDI-340246, in laboratory animals	5
Prediction of the neurotoxic mechanisms of the pesticide phorate using network toxicology, molecular docking, and molecular dynamics simulation	5
Defining the enzymes of xenobiotic metabolism - a forlorn hope?	5
Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human	5
2-Naphthalenemethanol participates in metabolic activation of 2-methylnaphthalene	5
Coptisine modulates the pharmacokinetics of florfenicol by targeting CYP1A2, CYP2C11 and CYP3A1 in the liver and P-gp in the jejunum of rats: a pilot study	5
Metabolic activation of deferiprone mediated by CYP2A6	5
Metabolism of gartanin in liver microsomes and its modulating effects on cytochrome P450s	5
The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma	5
Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species	4
Effects of tyrosine kinase inhibitors used for the treatment of non-small cell lung carcinoma on cytochrome P450 2J2 activities	4
Interactions of organophosphorus pesticides with ATP-binding cassette (ABC) drug transporters	4
Pharmacokinetics of intranasal drugs, still a missed opportunity?	4
Response to the comments raised by Fernando Tricta	4
Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats	4
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities	4
Investigation of the pharmacokinetics and metabolic fate of Fasiglifam (TAK-875) in male and female rats following oral and intravenous administration	4
Sodium dodecylbenzene sulphonate (SDBS) present in detergents: action on the gills, skin, and blood of D. rerio fish	4
How predictive are isolated perfused liver data of in vivo hepatic clearance? A meta-analysis of isolated perfused rat liver data	4
Metabolic profiling in liver microsomes and mice of E28, a potent FLT3 inhibitor	4
A physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) model for the insecticide dimethoate	4
Pharmacokinetics and multi-peak phenomenon analysis of novel anti-Parkinson’s drug FLZ after multi-dose in cynomolgus monkeys	4
Cytochrome P450 1A2 and 2C enzymes autoinduced by omeprazole in dog hepatocytes and human HepaRG and HepaSH cells are involved in omeprazole 5-hydroxylation and sulfoxidation	4
DEC1 negatively regulates CYP2B6 expression by binding to the CYP2B6 promoter region ascribed to IL-6-induced downregulation of CYP2B6 expression in HeLa cells	4
In vivo-in vitrocorrelation of antitumor activity of heat shock protein 90 (HSP90) inhibitors with a pharmacokinetics/pharmacodynamics analysis using NCI-N87 xenograft mice	4

Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects	4
Bioavailability and dose proportionality of a highly lipophilic phenolic antioxidant	4
Species differences in oxidative metabolism of regorafenib	4
Meeting report of the 3rd European Biotransformation Workshop	4
Species differences in liver microsomal hydrolysis of acyl glucuronide in humans and rats	4
Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury	4
Inorganic mercury pharmacokinetics in man: a hybrid model	4
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor	4
Effectiveness of pain care intervention combined with traditional Chinese medicine care in the perioperative care of patients with urinary stones	4
Preface for special issue: “Emerging strategies, technologies, and approaches for the next generation ADCs”	4
Characterisation of seven medications approved for attention-deficit/hyperactivity disorder usingin vitromodels of hepatic metabolism	4
Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir	4
The chlorophenoxy herbicide MCPA: a mechanistic basis for the observed differences in toxicological profile in humans and rats versus dogs	4
Drug-drug interaction between danshensu and irbesartan and its potential mechanism	4
Human and nonclinical disposition of [¹⁴C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection	4
Sanguinarine-induced proteomic changes in Methicillin-Resistant Staphylococcus aureus	4
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective	4
Impact of tectoridin on the pharmacokinetics of florfenicol via targeting cytochrome P450 and P-glycoprotein of rats	4
Meeting report: DMDG peptide and oligonucleotide ADME workshop 2024	4
Pharmacokinetics, tissue distribution, plasma protein binding rate and excretion of sinoacutine following intravenous administration in female and male Sprague-Dawley rats	4
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1)	4